As of close of business last night, CME Group Inc’s stock clocked out at $213.62, down -1.27% from its previous closing price of $216.36. In other words, the price has decreased by -$2.74 from its previous closing price. On the day, 1870169 shares were traded.
Ratios:
To gain a deeper understanding of CME’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 25.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 22.77. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Barclays on January 08, 2024, Downgraded its rating to Equal Weight and sets its target price to $222 from $244 previously.
On January 03, 2024, Goldman Downgraded its rating to Sell which previously was Neutral but kept the price unchanged to $195.
BofA Securities Upgraded its Underperform to Neutral on September 06, 2023, whereas the target price for the stock was revised from $167 to $204.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 18 ’24 when SHEPARD WILLIAM R bought 1,331 shares for $202.44 per share. The transaction valued at 269,488 led to the insider holds 253,060 shares of the business.
SHEPARD WILLIAM R bought 59 shares of CME for $11,880 on Jan 18 ’24. The Director now owns 2,322 shares after completing the transaction at $202.44 per share. On Dec 28 ’23, another insider, SHEPARD WILLIAM R, who serves as the Director of the company, bought 266 shares for $210.79 each. As a result, the insider paid 56,170 and bolstered with 251,729 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CME now has a Market Capitalization of 76.91B and an Enterprise Value of 77.31B. As of this moment, CME’s Price-to-Earnings (P/E) ratio for their current fiscal year is 24.11, and their Forward P/E ratio for the next fiscal year is 21.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 5.52. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.78 while its Price-to-Book (P/B) ratio in mrq is 2.87. Its current Enterprise Value per Revenue stands at 13.86 whereas that against EBITDA is 16.57.
Stock Price History:
The Beta on a monthly basis for CME is 0.50, which has changed by 18.66% over the last 52 weeks, in comparison to a change of 32.31% over the same period for the S&P500. Over the past 52 weeks, CME has reached a high of $222.63, while it has fallen to a 52-week low of $171.43. The 50-Day Moving Average of the stock is 210.23, while the 200-Day Moving Average is calculated to be 204.78.
Shares Statistics:
It appears that CME traded 1.77M shares on average per day over the past three months and 1.67M shares per day over the past ten days. A total of 359.23M shares are outstanding, with a floating share count of 358.76M. Insiders hold about 0.34% of the company’s shares, while institutions hold 89.26% stake in the company. Shares short for CME as of Feb 29, 2024 were 3.32M with a Short Ratio of 1.87, compared to 3.44M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.92% and a Short% of Float of 0.92%.
Dividends & Splits
With its trailing 12-month dividend rate of 4.40, CME has a forward annual dividend rate of 4.37. Against a Trailing Annual Dividend Yield of 2.03%, it implies a Forward Annual Dividend Yield of 4.03%. The stock’s 5-year Average Dividend Yield is 2.96. The current Payout Ratio is 108.90% for CME, which recently paid a dividend on Mar 26, 2024 with an ex-dividend date of Mar 07, 2024. Stock splits for the company last occurred on Jul 23, 2012 when the company split stock in a 5:1 ratio.
Earnings Estimates
As of right now, 14 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $2.45 for the current quarter, with a high estimate of $2.55 and a low estimate of $2.35, while EPS last year was $2.42. The consensus estimate for the next quarter is $2.4, with high estimates of $2.58 and low estimates of $2.2.
Analysts are recommending an EPS of between $10.3 and $9.06 for the fiscal current year, implying an average EPS of $9.59. EPS for the following year is $9.88, with 16 analysts recommending between $10.79 and $8.66.
Revenue Estimates
In the current quarter, 13 analysts expect revenue to total $1.47B. It ranges from a high estimate of $1.54B to a low estimate of $1.41B. As of the current estimate, CME Group Inc’s year-ago sales were $1.39B, an estimated increase of 5.90% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $1.46B, an increase of 8.80% over than the figure of $5.90% in the same quarter last year. There is a high estimate of $1.55B for the next quarter, whereas the lowest estimate is $1.34B.
A total of 16 analysts have provided revenue estimates for CME’s current fiscal year. The highest revenue estimate was $6.2B, while the lowest revenue estimate was $5.48B, resulting in an average revenue estimate of $5.84B. In the same quarter a year ago, actual revenue was $5.58B, up 4.80% from the average estimate. Based on 16 analysts’ estimates, the company’s revenue will be $6.07B in the next fiscal year. The high estimate is $6.41B and the low estimate is $5.7B. The average revenue growth estimate for next year is up 3.90% from the average revenue estimate for this year.
